No record found
No record found


* Returns not adjusted for payouts
Company Profile
BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.
Akhter Khalid Waheed | CEO |
Sebastian Martin Ferrarassi | Chairperson |
Abdur Rehman | Company Secretary |
CDC Share Registrar Services Limited, CDC House, 99-B, Block-B, S.M.C.H.S, Main Shahrah Faisal, Karachi
KPMG Taseer Hadi & Co. Chartered Accountants
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Feb 28, 2025 | Transmission of Quarterly Report for the Period Ended 31-12-2024 | View PDF |
Feb 28, 2025 | Financial Results for the Quarter Ended 2024-12-31 | View PDF |
Feb 28, 2025 | Financial Results for the Quarter Ended 2024-12-31 REVOKED | |
Oct 30, 2024 | Transmission of Quarterly Report for the Period Ended 2024-09-30 | View PDF |
Oct 28, 2024 | Financial Results for the Quarter Ended 2024-09-30 | View PDF |
Oct 25, 2024 | Transmission of Annual Report for the Year Ended 2024-06-30 | View PDF |
Date | Title | Document |
---|---|---|
Jan 14, 2025 | Material Information | View PDF |
Dec 24, 2024 | Clarification - Unusual Movement in Price of the Shares of the BF Biosciences Limited | View PDF |
Nov 26, 2024 | Corporate Briefing Session - Presentation | View PDF |
Nov 22, 2024 | Corporate Briefing Session | View PDF |
Nov 14, 2024 | Material Informaiton | View PDF |
Financials
All numbers in thousands (000's) except EPS
No Data Available |
---|
Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | |
---|---|---|---|---|
Sales | 1,327,202 | 1,386,372 | 2,915,514 | 888,193 |
Profit after Taxation | 80,539 | 115,273 | 314,052 | 52,400 |
EPS | 1.09 | 1.82 | 4.96 | 0.83 |
